ストックスクリーナーアプリを入手
5.52
0.18%
-0.01
アフターアワーズ：
5.51
-0.010
-0.18%
Scpharmaceuticals Inc (SCPH) 最新ニュース
Risk adjusted return profile for scPharmaceuticals Inc. analyzedQuarterly Market Review & High Return Trade Opportunity Guides - Newser
Published on: 2025-08-27 13:22:08 - Newser
What institutional flow reveals about scPharmaceuticals Inc.Forecast Cut & Precise Buy Zone Identification - Newser
Reversal indicators forming on scPharmaceuticals Inc. stock2025 Retail Activity & Low Drawdown Trading Techniques - Newser
Quantitative breakdown of scPharmaceuticals Inc. recent moveJuly 2025 Intraday Action & Free AI Powered Buy and Sell Recommendations - Newser
scPharmaceuticals Extends SmartDose Supply Agreement - MSN
MannKind Snaps Up scPharmaceuticals In Cardiorenal Expansion - insights.citeline.com
scPharmaceuticals downgraded to Hold from Buy at Craig-Hallum - MSN
What’s next for scPharmaceuticals Inc. stock priceEarnings Risk Report & Fast Momentum Entry Tips - Newser
scPharmaceuticals Investor Alert: Kahn Swick & Foti Investigates Proposed Sale to MannKind Corporation - AInvest
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc.SCPH - Business Wire
MannKind Announces Acquisition of scPharmaceuticals - MSN
MannKind Expands Cardiometabolic and Lung Portfolio with $360 Million Acquisition of scPharmaceuticals - Pharmaceutical Executive
Sector ETF performance correlation with scPharmaceuticals Inc.Quarterly Earnings Summary & Long-Term Capital Growth Strategies - Newser
MannKind stock price target raised to $8 by RBC on scPharmaceuticals deal - Investing.com Nigeria
Why scPharmaceuticals Inc. is moving todayEarnings Overview Report & AI Forecasted Entry and Exit Points - Newser
MannKind to acquire scPharmaceuticals - The Pharma Letter
Can scPharmaceuticals Inc. deliver consistent dividends2025 Analyst Calls & Verified Trade Idea Suggestions - sundaytimes.kr
Maxim Downgrades scPharmaceuticals to Hold From Buy - MarketScreener
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside - MSN
Real time pattern detection on scPharmaceuticals Inc. stock2025 Market Trends & Fast Entry Momentum Trade Alerts - Newser
scPharmaceuticals Extends SmartDose Supply Agreement Until 2027 - AInvest
scPharmaceuticals amends supply agreement with West Pharmaceutical Services By Investing.com - Investing.com Australia
MannKind to Acquire ScPharmaceuticals in $360M Deal - USA Herald
Cooley, Latham Lead $360M ScPharmaceuticals Acquisition - Law360
MannKind To Acquire scPharmaceuticals - citybiz
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal - Benzinga
Burlington biotech bought for $300M - The Business Journals
MannKind’s Strategic Acquisition of scPharmaceuticals: A Catalyst for Future Growth and Value Creation - TipRanks
Halper Sadeh LLC Investigates SCPH, VTLE, CRGY for Potential Securities Law Violations - AInvest
scPharmaceuticals Surges Amid Patent Approvals and Revenue Growth - timothysykes.com
CT maker of therapeutic inhalers agrees to acquire Mass. biopharma company in $360M deal - Hartford Business Journal
MannKind to buy scPharmaceuticals for up to $360M; Arnatar launches with $52M - Endpoints News
MannKind stock falls after announcing acquisition of scPharmaceuticals By Investing.com - Investing.com Australia
MannKind stock falls after announcing acquisition of scPharmaceuticals - Investing.com
SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders - Business Wire
MannKind to buy scPharmaceuticals to expand its cardiometabolic business - Seeking Alpha
MannKind Makes A $360 Million Move For ScPharmaceuticals - Finimize
M&A Snapshot: scPharmaceuticals rises on $360M acquisition deal by MannKind - MSN
ScPharmaceuticals Inc. Enters into an Amendment to That Certain Supply Agreement - MarketScreener
MannKind to acquire scPharmaceuticals for up to $6.35 per share - Investing.com India
MannKind to acquire scPharmaceuticals for up to $6.35 per share By Investing.com - Investing.com Canada
Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Scpharmaceuticals Soars 13.2% on MannKind Acquisition - AInvest
M&A Snapshot: scPharmaceuticals rises on $360M acquisition deal by MannKind (MNKD:NASDAQ) - Seeking Alpha
MannKind to Acquire scPharmaceuticals for Up to $360 Million - MarketScreener
scPharmaceuticals Announces Merger with MannKind Corporation - TipRanks
MannKind to Acquire scPharmaceuticals, Accelerating Revenue - GlobeNewswire
MannKind Acquires scPharmaceuticals, Boosting Revenue Growth and Leadership in Cardiometabolic and Lung Diseases - AInvest
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases - MarketScreener
$10B Market Opportunity: MannKind Acquires FUROSCIX Maker scPharmaceuticals to Dominate Cardiorenal Space - Stock Titan
$10B Market Opportunity: MannKind Acquires FUROSCIX Maker scPharmaceuticals in Strategic Cardiorenal Expansion - Stock Titan
Technical analysis overview for scPharmaceuticals Inc. stockDollar Strength & Entry and Exit Point Strategies - Newser
Can a trend reversal in scPharmaceuticals Inc. lead to recovery2025 Market Sentiment & Weekly Stock Breakout Alerts - Newser
What earnings revisions data tells us about scPharmaceuticals Inc.July 2025 Volume & Fast Gain Swing Trade Alerts - Newser
Will scPharmaceuticals Inc. Stock Benefit from AI and Green Energy TrendsEarnings Trend Report & Safe Capital Growth Trade Ideas - Newser
0.98%
8.06%
大文字化:
|
ボリューム (24 時間):